Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with integrated commercial and drug development operations with a focus in hematology and oncology. In the United States, it markets two oncology drugs, ZEVALIN and FUSILEV and have two drugs, apaziquone and belinostat, in late stage development along with a pipeline of drug candidates. Apaziquone is studied in two phase-III clinical trials for non-muscle invasive bladder cancer (NMIBC), under strategic collaborations with Allergan, Inc. (Allergan), Nippon Kayaku Co. Ltd. (Nippon Kayaku), and Handok Pharmaceuticals Co. Ltd. (Handok). Belinostat is being studied in multiple indications, including a phase-II registrational trial for relapsed or refractory peripheral T-cell lymphoma (PTCL), under a strategic collaboration with TopoTarget A/S (TopoTarget). On September 5, 2012, it acquired Allos Therapeutics, Inc.